Search research articles
Contact Us
Filters
Showing results (31-40 of 76) with videos related to
Page
of 8
Sort By:
Targeted Oncology
|
July 4, 2013
Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT
M Di Bartolomeo, F Pietrantonio, F Perrone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2014
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation
F Pietrantonio, F Perrone, F de Braud, et al.
ESMO Open
|
October 19, 2024
Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups
A G Leone, A S Mai, K Y Fong, et al.
Frontiers in Public Health
|
July 15, 2024
Applications to augment patient care for Internal Medicine specialists: a position paper from the EFIM working group on telemedicine, innovative technologies & digital health
F Pietrantonio, M Florczak, S Kuhn, et al.
ESMO Open
|
October 2, 2024
Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study
F Tosi, L Salvatore, E Tamburini, et al.
ESMO Open
|
June 4, 2023
Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology
A G Leone, R Miceli, D Trapani, et al.
ESMO Open
|
October 24, 2021
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO
D Rossini, A Boccaccino, A Sbrana, et al.
The Pharmacogenomics Journal
|
March 23, 2016
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab
F S Falvella, C Cremolini, R Miceli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2024
Corrigendum to "Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments": [Annals of Oncology 34 (2023) 543-552]
J Ros, J Matito, G Villacampa, et al.
ESMO Open
|
February 5, 2025
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study
C Antoniotti, M Carullo, D Rossini, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 76) with videos related to
Sort By:
Page
of 8
Targeted Oncology
|
July 4, 2013
Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT
M Di Bartolomeo, F Pietrantonio, F Perrone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2014
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation
F Pietrantonio, F Perrone, F de Braud, et al.
ESMO Open
|
October 19, 2024
Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups
A G Leone, A S Mai, K Y Fong, et al.
Frontiers in Public Health
|
July 15, 2024
Applications to augment patient care for Internal Medicine specialists: a position paper from the EFIM working group on telemedicine, innovative technologies & digital health
F Pietrantonio, M Florczak, S Kuhn, et al.
ESMO Open
|
October 2, 2024
Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study
F Tosi, L Salvatore, E Tamburini, et al.
ESMO Open
|
June 4, 2023
Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology
A G Leone, R Miceli, D Trapani, et al.
ESMO Open
|
October 24, 2021
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO
D Rossini, A Boccaccino, A Sbrana, et al.
The Pharmacogenomics Journal
|
March 23, 2016
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab
F S Falvella, C Cremolini, R Miceli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2024
Corrigendum to "Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments": [Annals of Oncology 34 (2023) 543-552]
J Ros, J Matito, G Villacampa, et al.
ESMO Open
|
February 5, 2025
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study
C Antoniotti, M Carullo, D Rossini, et al.
Page
of 8